ABBISKO-B (02256) opened high by over 6%, reaching a historical high of HK$18.92. As of press time, the stock was up 3.87% to HK$18.5 with a trading volume of HK$56,300.

On the news front, ABBISKO recently announced that the IND application for the combination therapy of its investigational oral PD-L1 inhibitor ABSK043 and Eleris' KRAS G12C inhibitor glecirasib tablets for treating KRAS G12C-mutated NSCLC has been approved in China. In March this year, the company reached a cooperation agreement with Eleris regarding ABSK043. The current approval is for a Phase II clinical trial evaluating the combination of ABSK043 and Eleris' KRAS G12C inhibitor glecirasib tablets in treating KRAS G12C-mutated NSCLC.

Additionally, on August 13, according to MSCI's latest August index review results, the company was successfully included as a constituent stock in the MSCI Global Small Cap Index, with the adjustment taking effect after market close on August 26. On August 15, AllianzSE increased its holdings in ABBISKO, raising AllianzSE's shareholding ratio from 4.81% to 5.10%. The company has now attracted investments from multiple prominent foreign investors including Lilly Asia Ventures, Qiming Venture Partners, Morgan Stanley, and AllianzSE.

The company repurchased 200,000 shares on August 27 and another 100,000 shares on August 28. As of June 30, 2025, the company has cumulatively repurchased 9.545 million shares, totaling HK$75.3 million.